scispace - formally typeset
X

Xiao-Rong Liu

Researcher at Kettering University

Publications -  12
Citations -  673

Xiao-Rong Liu is an academic researcher from Kettering University. The author has contributed to research in topics: Human leukocyte antigen & Interleukin 15. The author has an hindex of 7, co-authored 12 publications receiving 640 citations. Previous affiliations of Xiao-Rong Liu include Memorial Sloan Kettering Cancer Center.

Papers
More filters
Journal ArticleDOI

Killer Ig-Like Receptor Haplotype Analysis by Gene Content: Evidence for Genomic Diversity with a Minimum of Six Basic Framework Haplotypes, Each with Multiple Subsets

TL;DR: The studies support a model for KIR haplotype diversity based on six basic gene compositions, and suggest that the centromeric half of the KIR genomic region is comprised of three major combinations, while the telomeric half can assume a short form with either 2DS4 or KIR1D or a long form with multiple combinations of several stimulatory KIR genes.
Journal ArticleDOI

Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell–depleted allogeneic hematopoietic cell transplantation

TL;DR: It is confirmed that NK alloreactivity can occur in HLA-matched HSCT, whereolerance to self is either acquired by the stem cell-derived NK cell after exiting the bone marrow or where tolerance to self can be temporarily overcome.
Journal ArticleDOI

NK Cell Tolerance of Self-Specific Activating Receptor KIR2DS1 in Individuals with Cognate HLA-C2 Ligand

TL;DR: It is demonstrated that many NK cells with anti–HLA-C2 reactivity are present in HLA-C1 homozygous and heterozygous donors with 2 DS1, and 2DS1 positive clones from HLA/C2 homozygOUS donors are frequently tolerant to HLA,C2.
Journal ArticleDOI

Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections.

TL;DR: A novel in‐vitro system for generation of stable 15Rα/15 complexes that represent a potent adjuvant for augmenting the efficacy of adoptive immunotherapy and could be developed for use in combination immunotherapy approaches.